Summary of Key Points Core Viewpoint - The company has approved a guarantee amounting to a total of RMB 422,100 million for its wholly-owned and controlling subsidiaries to address liquidity issues and support their development [1][2]. Group 1: Guarantee Overview - As of July 2025, the total guarantee amount provided to the subsidiaries is RMB 240,068.37 million, which includes previously provided guarantees of RMB 223,804.44 million and a new guarantee of RMB 16,263.93 million [1]. - The company will provide joint liability guarantees for its subsidiaries to apply for credit facilities from financial institutions [1][2]. Group 2: Internal Decision-Making Process - The guarantee proposal was approved by the company's board on April 24, 2025, with a unanimous vote of 11 in favor [2]. - The proposal was subsequently ratified at the annual shareholders' meeting on May 27, 2025 [2]. Group 3: Necessity and Reasonableness of Guarantees - The loans guaranteed by the company are essential for the project construction and daily operations of the subsidiaries, which aligns with the company's overall development strategy [5][6]. - The company maintains real-time monitoring of the cash flow and financial changes of its subsidiaries, ensuring that risks remain within controllable limits [5][6]. Group 4: Financial Health and Debt Capacity - The subsidiaries have strong debt repayment capabilities, with the latest asset-liability ratio of Hangzhou RunDa exceeding 70%, indicating a need for support to enhance operational financing [5][6]. - As of the announcement date, the total external guarantees provided by the company and its subsidiaries amount to RMB 512,100 million, with no overdue guarantees reported [7].
上海润达医疗科技股份有限公司关于上月为子公司担保的进展情况公告